Fig. 3

PK5-RL-Gal-3C inhibits angiogenesis in vivo and in vitro. Tube formation assay in vitro was performed to determine the inhibitory effect of rPK5-RL-Gal-3C on angiogenesis according to the materials and methods. A and B rPK5-RL-Gal-3C exhibited stronger inhibitory action than E25, rPK5 and rGal-3C on tube formation in vitro. After treated with H1/EEV and H1/EEV-PK5-RL-Gal-3C nanoparticles, the tumors were removed and stained by CD31 antibody using IHC. C and D H1/EEV-PK5-RL-Gal-3C treatment down-regulated the expression of CD31 in tumor tissues. VEGF-induced matrigel plug assay in vivo were performed to determine the inhibitory effect of rPK5-RL-Gal-3C on angiogenesis according to the materials and methods. E rPK5-RL-Gal-3C exhibited stronger inhibitory action than rPK5 and rGal-3C in VEGF-induced matrigel plug assay model in vivo. F and G lactose partially blockaded the inhibitory action of rPK5-RL-Gal-3C but not sucrose. Significant differences are denoted by * for p < 0.05, ** for p < 0.01, *** for p < 0.001 and ns, no significance